- Home
- VTGN vs RAND Comparison
VTGN vs RAND Comparison
Compare VTGN & RAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VTGN | RAND |
|---|---|---|
| Founded | 1998 | 1969 |
| Country | United States | United States |
| Employees | N/A | 4 |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.8M | 31.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | VTGN | RAND |
|---|---|---|
| Price | $0.53 | $11.03 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $0.90 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 5.6K |
| Earning Date | 02-12-2026 | 03-09-2026 |
| Dividend Yield | N/A | ★ 10.87% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $721,000.00 | ★ $7,327,287.00 |
| Revenue This Year | $87.21 | N/A |
| Revenue Next Year | $256.22 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.54 | $10.56 |
| 52 Week High | $5.14 | $31.89 |
Technical Indicators
Market Signals| Indicator | VTGN | RAND |
|---|---|---|
| Relative Strength Index (RSI) | 25.10 | 33.52 |
| Support Level | $0.54 | $11.00 |
| Resistance Level | $0.60 | $11.40 |
| Average True Range (ATR) | 0.04 | 0.34 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 8.20 | 0.00 |
Price Performance
Historical ComparisonAbout VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.